Immutep

Contact Us

Immutep S.A. au capital de 247 136 euros- 439 518 663 RCS Evry Siège social : Parc Club Orsay, 2, rue Jean Rostand, 91893 ORSAY



Filling this form is the simpliest way to contact us by email.


If you wish to visit us, please click here for full maps and details.

First Name :

Last Name :

Company (blank if none) :

Title (blank if none) :

Address :

Town :

Zip Code :

Country :

Telephone :

Fax :

E-mail address :

<~ only this field is really required
 

Type in your comments or questions. An Immutep staff member will get back to you shortly.

» Visit Us
© 2002 Immutep, S.A.
Press Release
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...
10/2009 - New results confirm that ImmuFact IMP321 doubles clinical response rate
image Immutep S.A. announced today interim results from the first three ...
09/2009 - Clinical research paper describes IMP321’s potency in inducing progression-free survival improvement and effector memory T cells
image Immutep S.A. announced today the publication of a clinical research ...
04/2009 - A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer has started at Washington University in Saint Louis (MO)
image Immutep S.A. announced today the first administration of IMP321 in ...